Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice

Infection and Immunity

Volumn 76, Issue 1, 2008, Pages 97-102

  Saville, Stephen P ^a   Lazzell, Anna L ^a   Chaturvedi, Ashok K ^a   Monteagudo, Carlos ^b   Lopez Ribot, Jose L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CORTISONE ACETATE; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE ACTIVATION; CANDIDA ALBICANS; CELL SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FUNGAL VIRULENCE; GENETIC ENGINEERING; GENETIC MANIPULATION; IMMUNE DEFICIENCY; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY; STRAIN IDENTIFICATION; SYSTEMIC DISEASE; T LYMPHOCYTE ACTIVATION; YEAST CELL;

ANIMALS; CANDIDA ALBICANS; CANDIDIASIS; DOXORUBICIN; FEMALE; FUNGAL PROTEINS; GENETIC ENGINEERING; KIDNEY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, NUDE; MICE, SCID; TIME FACTORS;

EID: 37749025729     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00982-07     Document Type: Article

References (28)

1. Ashman, R. B., and J. M. Papadimitriou. 1987. Murine candidiasis. Pathogenesis and host responses in genetically distinct inbred mice. Immunol. Cell Biol. 65:163-171.
2. Ashman, R. B., J. M. Papadimitriou, A. Fulurija, K. E. Drysdale, C. S. Farah, O. Naidoo, and T. Gotjamanos. 2003. Role of complement C5 and T lymphocytes in pathogenesis of disseminated and mucosal candidiasis in susceptible DBA/2 mice. Microb. Pathog. 34:103-113.
3. Balish, E., J. Jensen, T. Warner, J. Brekke, and B. Leonard. 1993. Mucosal and disseminated candidiasis in gnotobiotic SCID mice. J. Med. Vet. Mycol. 31:143-154.
4. Banerjee, S. N., T. G. Emori, D. H. Culver, R. P. Gaynes, W. R. Jarvis, T. Horan, J. R. Edwards, J. Tolson, T. Henderson, and W. J. Martone. 1991. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am. J. Med. 91:86S-89S.
5. Beck-Sague, C., and W. R. Jarvis. 1993. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J. Infect. Dis. 167:1247-1251.
6. Calderone, R. A., and W. A. Fonzi. 2001. Virulence factors of Candida albicans. Trends Microbiol. 9:327-335.
7. Casadevall, A., and L. Pirofski. 2001. Host-pathogen interactions: the attributes of virulence. J. Infect. Dis. 184:337-344.
8. Casadevall, A., and L. A. Pirofski. 1999. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect. Immun. 67:3703-3713.
9. Casadevall, A., and L. A. Pirofski. 2003 Microbial virulence results from the interaction between host and microorganism. Trends Microbiol. 11:157-158. (Author reply, 11:158-159.)
10. Casadevall, A., and L. A. Pirofski. 2002. What is a pathogen? Ann. Med. 34:2-4.
11. Cinader, B., S. Dubiski, and A. C. Wardlaw. 1966. Genetics of MuB1 and of a complement defect in inbred strains of mice. Genet. Res. 7:32-43.
12. Cutler, J. E. 1991. Putative virulence factors of Candida albicans. Annu. Rev. Microbiol. 45:187-218.
13. Lee, K. W., and E. Balish. 1981. Systemic candidosis in germfree, flora-defined and conventional nude and thymus-bearing mice. J. Reticuloendothel. Soc. 29:71-77.
14. Levitz, S. M. 1992. Overview of host defenses in fungal infections. Clin. Infect. Dis. 14(Suppl. 1):S37-S42.
15. Lo, H. J., J. R. Kohler, B. DiDomenico, D. Loebenberg, A. Cacciapuoti, and G. R. Fink. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell 90:939-949.
16. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
17. Romani, L. 2004. Immunity to fungal infections. Nat. Rev. Immunol. 4:1-23.
18. Romani, L. 2000. Innate and adaptive immunity in Candida albicans infections and saprophytism. J. Leukoc. Biol. 68:175-179.
19. Rooney, P. J., and B. S. Klein. 2002. Linking fungal morphogenesis with virulence. Cell Microbiol. 4:127-137.
20. Saville, S. P., A. L. Lazzell, A. P. Bryant, A. Fretzen, A. Monreal, E. O. Solberg, C. Monteagudo, J. L. Lopez-Ribot, and G. T. Milne. 2006. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob. Agents Chemother. 50:3312-3316.
21. Saville, S. P., A. L. Lazzell, C. Monteagudo, and J. L. Lopez-Ribot. 2003. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot. Cell 2:1053-1060.
22. Sheppard, D. C., G. Rieg, L. Y. Chiang, S. G. Filler, J. E. Edwards, Jr., and A. S. Ibrahim. 2004. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 48:1908-1911.
23. Shoham, S., and S. M. Levitz. 2005. The immune response to fungal infections. Br. J. Haematol. 129:569-582.
24. Stephens-Romero, S. D., A. J. Mednick, and M. Feldmesser. 2005. The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy. Infect. Immun. 73:114-125.
25. Vespa, M. N., J. L. Lopez-Ribot, and W. L. Chaffin. 1995. Adherence of germ tubes of Candida albicans to tissues from immunocompromised mice. FEMS Immunol. Med. Microbiol. 11:57-63.
26. Viudes, A., J. Peman, E. Canton, P. Ubeda, J. L. Lopez-Ribot, and M. Gobernado. 2002. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur. J. Clin. Microbiol. Infect. Dis. 21:767-774.
27. Wetsel, R. A., D. T. Fleischer, and D. L. Haviland. 1990. Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5′-exon. J. Biol. Chem. 265:2435-2440.
28. Wey, S. B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1988. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch. Intern. Med. 148:2642-2645.